LGD-4033 vs RAD-140: What Does the Research Actually Show?
LGD-4033 vs RAD-140 is a common comparison among people researching selective androgen receptor modulators (SARMs). Researchers and suppliers also call LGD-4033 Ligandrol, while many sources refer to RAD-140 as Testolone.
Online bodybuilding discussions often describe LGD-4033 as better for muscle mass and RAD-140 as better for strength, harder-looking muscles or performance. However, clinical research does not support these claims with sufficient comparative human evidence.
No reliable clinical evidence establishes that LGD-4033 is better than RAD-140, or vice versa, for bodybuilding. Researchers have investigated the two compounds in different clinical settings, so we cannot compare their findings as if they came from a head-to-head trial.
This guide examines the available research, including muscle-related outcomes, testosterone suppression, half-life, potential side effects and regulatory considerations in Australia.
LGD-4033 vs RAD-140: Quick Comparison
| Feature | LGD-4033 (Ligandrol) | RAD-140 (Testolone) |
|---|---|---|
| Compound | Selective androgen receptor modulator | Selective androgen receptor modulator |
| Human clinical research | Phase I study in 76 healthy men | Phase I study in 22 postmenopausal women with metastatic breast cancer |
| Main research context | Safety, pharmacokinetics and body composition | Safety, pharmacokinetics and potential anti-cancer activity |
| Reported human half-life | Approximately 24–36 hours | Approximately 44.7 hours in the Phase I oncology study |
| Lean body mass | Dose-dependent increase in a short controlled study | No established bodybuilding benefit |
| Muscle strength | No statistically significant improvement in the short study | No established bodybuilding benefit |
| Testosterone-related effects | Dose-dependent suppression of total testosterone and SHBG in the controlled study | Researchers observed SHBG reductions in the oncology study; direct comparisons of testosterone suppression remain unavailable |
| Important safety signals | Hormonal and lipid changes | Liver enzyme elevations in the oncology study and published liver-injury case reports |
| Long-term safety for bodybuilding | Researchers have not established it | Researchers have not established it |
The studies involved different populations, research objectives and clinical conditions. This table compares the available evidence; it does not recommend either compound.
What Is LGD-4033 (Ligandrol)?
LGD-4033, also known as Ligandrol or VK5211, is an investigational non-steroidal selective androgen receptor modulator.
The compound binds to androgen receptors, which help regulate biological processes involving muscle and bone tissue.
Researchers have investigated LGD-4033 because of its potential medical applications, including conditions involving muscle loss. However, these research objectives do not establish that it works as a safe or effective bodybuilding product.
What Did the Human LGD-4033 Study Find?
One of the most important studies was a randomized, double-blind, placebo-controlled trial involving 76 healthy men aged 21–50.
Researchers administered LGD-4033 or placebo over 21 days. They then assessed safety, pharmacokinetics, hormone levels and changes in body composition.
The researchers reported:
- A dose-dependent increase in lean body mass.
- No statistically significant change in fat mass.
- Dose-dependent suppression of total testosterone and sex hormone-binding globulin (SHBG).
- Changes in HDL cholesterol and triglyceride levels.
- No statistically significant improvement in muscle strength or stair-climbing performance during the short study.
Hormone and lipid measurements returned to baseline during the follow-up period. This finding applies to the controlled study conditions and does not guarantee the same outcome for other people or patterns of exposure.
The important distinction: an increase in lean body mass does not automatically mean a measurable improvement in muscle strength, athletic performance or long-term health.
The study also lasted only three weeks. It cannot establish long-term safety or predict the effects of recreational bodybuilding use.
Read the published research: The Safety, Pharmacokinetics, and Effects of LGD-4033 — PubMed.
What Is RAD-140 (Testolone)?
RAD-140, commonly known as Testolone, is another investigational selective androgen receptor modulator.
Researchers have investigated its interaction with androgen receptors and explored its potential biological effects in preclinical research.
However, claims about its anabolic potency, muscle-building performance or superiority over other SARMs do not represent established clinical findings.
Unlike LGD-4033, which researchers studied in a controlled trial involving healthy men, RAD-140 has undergone a notable first-in-human trial involving postmenopausal women with advanced breast cancer.
What Did Human Research on RAD-140 Find?
A Phase I clinical study published in 2022 investigated RAD-140 in 22 heavily pretreated postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.
Researchers primarily examined safety, tolerability, pharmacokinetics and potential anti-tumour activity.
The study reported:
- Elevated AST in 59.1% of participants.
- Elevated ALT in 45.5%.
- Elevated total bilirubin in 27.3%.
- A reported terminal half-life of approximately 44.7 hours.
- Decreased SHBG in participants with available measurements.
- Preliminary evidence of anti-tumour activity in a limited number of participants.
Readers should interpret these findings in their clinical context. The participants had advanced cancer and had received previous treatments. Researchers did not design the study to evaluate muscle growth, athletic performance or bodybuilding outcomes in healthy men.
The reported liver enzyme elevations provide an important safety signal. However, the frequency of these outcomes in this small oncology study does not establish the risk among healthy recreational users.
What does this mean for the comparison? RAD-140 has undergone human clinical research, but that research does not establish its effectiveness or safety for bodybuilding.
Read the published research: A First-in-Human Phase 1 Study of RAD140 — PubMed.
LGD-4033 vs RAD-140: Which Is Better for Muscle Growth?
No reliable head-to-head clinical trial establishes which compound produces greater muscle growth in humans.
The available research differs substantially between the two compounds. One controlled trial examined LGD-4033 in healthy men and measured changes in lean body mass. By contrast, researchers studied RAD-140 in women with metastatic breast cancer, focusing on safety and potential anti-tumour activity.
Online claims that LGD-4033 produces greater total mass while RAD-140 creates harder or more defined muscles do not represent established clinical conclusions.
It is also important to distinguish lean body mass from skeletal muscle. Lean body mass includes body components other than muscle, and changes in this measurement do not automatically demonstrate greater strength or athletic performance.
Conclusion: Current evidence does not justify ranking LGD-4033 and RAD-140 by expected muscle gains.
LGD-4033 vs RAD-140: Strength and Performance
Neither compound has demonstrated a reliable bodybuilding performance advantage over the other in comparative human trials.
The LGD-4033 study measured leg-press strength and stair-climbing performance. Despite changes in lean body mass, the researchers found no statistically significant improvement in these performance measures over the short study period.
The RAD-140 oncology study did not measure strength or athletic performance.
Consequently, claims that RAD-140 works better for strength or that LGD-4033 produces superior overall performance remain unsupported by adequate comparative clinical evidence.
LGD-4033 vs RAD-140: Testosterone Suppression
Hormonal effects form an important part of any comparison involving SARMs.
LGD-4033 and Testosterone
The controlled human study of LGD-4033 found dose-dependent suppression of total testosterone and SHBG.
Researchers also observed significant suppression of free testosterone and follicle-stimulating hormone at the highest dose they investigated.
These findings demonstrate that LGD-4033 can affect hormone-related measurements, even during a relatively short clinical study.
RAD-140 and Testosterone
The Phase I RAD-140 oncology study reported decreases in SHBG among participants with available measurements.
However, SHBG and testosterone are different measurements. A change in SHBG does not automatically demonstrate direct testosterone suppression.
The available evidence does not establish a reliable head-to-head comparison showing that RAD-140 suppresses testosterone more than LGD-4033.
Is RAD-140 More Suppressive Than LGD-4033?
Researchers do not have enough comparative human evidence to establish a universal ranking.
The two compounds underwent studies in different populations and clinical settings. Their results cannot establish which one produces greater hormonal suppression in healthy men who use them for bodybuilding.
Claims that one compound causes only mild suppression while the other always causes severe suppression go beyond what the available evidence supports.
LGD-4033 vs RAD-140: Half-Life
Half-life describes the time required for a substance’s concentration in the body to decrease by approximately half under specified conditions.
It provides a pharmacokinetic measurement, not proof of effectiveness, safety or an optimal administration schedule.
LGD-4033 Half-Life
The controlled human LGD-4033 study reported an elimination half-life of approximately 24–36 hours.
Researchers also observed dose-proportional accumulation during repeated administration under the study conditions.
These findings describe LGD-4033 pharmacokinetics in that particular clinical setting. They do not establish a suitable personal dosing schedule or guarantee how long the compound will remain detectable.
RAD-140 Half-Life
The first-in-human Phase I study of RAD-140 reported a terminal half-life of approximately 44.7 hours.
Researchers obtained this result from a clinical study involving postmenopausal women with metastatic breast cancer.
This measurement does not represent a universal estimate for every individual. Nor does it establish an optimal bodybuilding schedule.
LGD-4033 vs RAD-140 Half-Life: What Is the Difference?
| Compound | Reported human half-life | Research context |
|---|---|---|
| LGD-4033 | 24–36 hours | Healthy men in a controlled Phase I study |
| RAD-140 | 44.7 hours | Postmenopausal women with metastatic breast cancer in a Phase I study |
RAD-140 showed a longer reported half-life in its Phase I study. However, researchers studied the two compounds in different populations and under different clinical conditions. These figures therefore do not establish a definitive pharmacokinetic comparison.
For related information, read our guide to how long SARMs stay in your system.
LGD-4033 vs RAD-140: Side Effects and Safety
Researchers have not established the long-term safety profile of either compound for bodybuilding use.
Available clinical research and published safety reports identify different concerns.
LGD-4033: Potential Safety Concerns
The controlled LGD-4033 study identified:
- Suppression of total testosterone and SHBG.
- Changes in HDL cholesterol and triglyceride levels.
- Dose-dependent changes in other hormone measurements.
Published reports have also associated SARM-containing products with liver injury. Some reports involved products containing more than one compound, which makes it difficult to identify the individual cause.
RAD-140: Potential Safety Concerns
The first-in-human clinical study identified frequent elevations in liver enzymes and bilirubin among participants.
Separate published case reports have also described drug-induced liver injury following RAD-140 use outside controlled clinical research.
These reports do not establish how frequently liver injury occurs. However, they show why claims that RAD-140 offers a harmless alternative to anabolic steroids lack adequate support.
Can You Compare Their Side Effects Directly?
The available evidence does not support a reliable direct comparison.
The LGD-4033 study involved healthy men over 21 days. The RAD-140 study involved women with advanced cancer who received investigational treatment.
The populations, clinical conditions and research objectives differed. Therefore, we cannot use the percentages from these studies to declare one compound safer than the other for recreational bodybuilding.
Product quality introduces another uncertainty. Products sold online may contain different amounts of active ingredients than their labels state, or they may include undeclared substances.
The Australian TGA has specifically warned that certain unapproved RAD-140 products contained significantly less active ingredient than advertised.
For more information, see the TGA safety advisory on unapproved SARMs.
Can You Stack LGD-4033 and RAD-140?
Some bodybuilding communities discuss combining LGD-4033 and RAD-140.
However, robust clinical research has not established the safety or benefits of combining these two investigational compounds for bodybuilding.
Combining substances can introduce additional uncertainty about their individual and combined effects. It can also make it harder to identify the cause of an adverse reaction.
Claims that combining LGD-4033 and RAD-140 guarantees greater muscle growth or reduces side effects lack reliable clinical support.
Researchers have not established an evidence-based stacking protocol that anyone can safely follow.
Are LGD-4033 and RAD-140 Legal in Australia?
The regulatory status of SARMs in Australia deserves careful attention.
The Therapeutic Goods Administration (TGA) classifies SARMs as prescription-only medicines in Australia.
The TGA has also warned consumers about unapproved products containing RAD-140 and other SARMs that regulators have not assessed for quality, safety or efficacy.
The fact that a website advertises a product or labels it “for research purposes only” does not establish approval for human use or prove that the seller can legally supply it.
For current information, consult the Therapeutic Goods Administration.
Are LGD-4033 and RAD-140 Banned in Sport?
Yes. The World Anti-Doping Agency (WADA) lists both LGD-4033 (Ligandrol) and RAD-140 (Testolone) as prohibited anabolic agents under its 2026 Prohibited List.
The list took effect on 1 January 2026 and prohibits these substances both in and out of competition.
Athletes subject to anti-doping regulations should consult the current list and the rules of their sporting organisation.
Official reference: WADA 2026 Prohibited List.
LGD-4033 vs RAD-140: Frequently Asked Questions
Is LGD-4033 better than RAD-140?
There is insufficient comparative human evidence to establish that LGD-4033 is better than RAD-140 for muscle growth, strength or athletic performance. Researchers investigated the compounds in different populations and settings.
Is RAD-140 stronger than LGD-4033?
Claims that one compound is stronger or more anabolic than the other lack support from reliable head-to-head clinical research. Laboratory potency and receptor activity do not automatically predict bodybuilding outcomes.
Which causes more testosterone suppression: LGD-4033 or RAD-140?
The available evidence does not establish a reliable comparative ranking. LGD-4033 produced dose-dependent changes in testosterone and SHBG in a controlled study. RAD-140 research reported changes in SHBG, but this does not establish greater testosterone suppression.
What is the half-life of LGD-4033?
A controlled human study reported an elimination half-life of approximately 24–36 hours.
What is the half-life of RAD-140?
A Phase I clinical study involving women with metastatic breast cancer reported a terminal half-life of approximately 44.7 hours. This finding applies to the conditions of that specific study.
Does LGD-4033 burn fat?
The short controlled human study did not demonstrate a significant reduction in fat mass. Researchers therefore have not established LGD-4033 as a clinically proven fat-loss compound.
Does RAD-140 cause liver damage?
Clinical research reported liver enzyme elevations among participants receiving RAD-140. Published case reports have also described liver injury associated with its use. Researchers have not established the frequency of these outcomes among recreational users.
Can you combine LGD-4033 and RAD-140?
Robust clinical research has not established that combining the two compounds is safe or effective. This article does not recommend a combined-use protocol.
Are LGD-4033 and RAD-140 anabolic steroids?
Both compounds belong to the selective androgen receptor modulator category rather than the conventional anabolic steroid category. However, their different classification does not make them risk-free or establish approval for bodybuilding use.
Conclusion: LGD-4033 vs RAD-140
Current research does not establish a clear winner between LGD-4033 and RAD-140 for bodybuilding.
LGD-4033 has undergone a controlled trial involving healthy men. Researchers found an increase in lean body mass but also identified hormonal and lipid changes. The study did not demonstrate statistically significant improvements in muscle strength or fat mass.
RAD-140 has undergone a first-in-human clinical trial involving women with metastatic breast cancer. That study provides important pharmacokinetic and safety information, but it does not establish muscle-building benefits in healthy people.
The key difference lies in the type and context of the available evidence — not a proven advantage in bodybuilding performance.
Both compounds have important safety and regulatory limitations. Online comparisons that confidently rank them for muscle growth, strength or testosterone suppression often go beyond what clinical research can establish.
Sources and Further Reading
- LGD-4033: Safety, Pharmacokinetics and Effects in Healthy Young Men — PubMed
- LGD-4033 Clinical Study — Full Text, PMC
- RAD-140: First-in-Human Phase I Clinical Study — PubMed
- RAD-140 Drug-Induced Liver Injury — PubMed
- Severe Liver Injury Following RAD-140 Use — Australian Prescriber
- TGA Safety Advisory: Unapproved SARMs
- WADA 2026 Prohibited List
